Drug lookup | Fillwise

OXAZEPAM

3 general benefit · 3 not a benefit

Other products in the same Health Canada class (N05BA) — coverage varies; not interchangeable

Alprazolam (Xanax): general benefit, Not a benefit
Bromazepam (Lectopam): general benefit, Not a benefit
Chlordiazepoxide (Librium): general benefit, Not a benefit
Clorazepate dipotassium (Tranxene): general benefit, Not a benefit
Diazepam (Diazepam Injection USP): general benefit, Limited Use 481, Not a benefit
Lorazepam (Apo-Lorazepam): general benefit, Not a benefit

1 more in the class list below

Apo-Oxazepam · DIN 00402680 · 10mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Apo-Oxazepam · DIN 00402680 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 1979-12-31 · brand APO-OXAZEPAM · ATC N05BA04 OXAZEPAM · form Tablet · route Oral · ingredients OXAZEPAM 10 MG · company Apotex inc · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Apo-Oxazepam: Formulary list price $0.0350/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0350 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3463 · Verify on the e-Formulary ↗ (DIN 00402680)

Source record

DIN 00402680: Apo-Oxazepam Raw flags: sec3=Y Item: 281608052; group id 499; item number 1291; lccId None; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.0350; ministry $0.0350 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00402680 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3463

Interchangeable products

Serax · DIN 02043653 · not recorded

Shortage status: resolved shortage (ended 2022-09-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00402680

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Oxazepam · DIN 00402745 · 15mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Apo-Oxazepam · DIN 00402745 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 1979-12-31 · brand APO-OXAZEPAM · ATC N05BA04 OXAZEPAM · form Tablet · route Oral · ingredients OXAZEPAM 15 MG · company Apotex inc · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Apo-Oxazepam: Formulary list price $0.0550/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0550 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 00402745: Apo-Oxazepam Raw flags: sec3=Y Item: 281608051; group id 499; item number 1292; lccId None; manufacturer id APX Source form: Tab; strength: 15mg Recorded listing: General benefit Source prices (unrounded): $0.0550; ministry $0.0550 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00402745 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3465

Interchangeable products

Serax · DIN 02043661 · not recorded

Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00402745

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Oxazepam · DIN 00402737 · 30mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Apo-Oxazepam · DIN 00402737 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 1979-12-31 · brand APO-OXAZEPAM · ATC N05BA04 OXAZEPAM · form Tablet · route Oral · ingredients OXAZEPAM 30 MG · company Apotex inc · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Apo-Oxazepam: Formulary list price $0.0750/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0750 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 00402737: Apo-Oxazepam Raw flags: sec3=Y Item: 281608050; group id 499; item number 1293; lccId None; manufacturer id APX Source form: Tab; strength: 30mg Recorded listing: General benefit Source prices (unrounded): $0.0750; ministry $0.0750 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00402737 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3464

Interchangeable products

Serax · DIN 02043688 · not recorded

Shortage status: resolved shortage (ended 2025-08-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00402737

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Serax · DIN 02043653 · 10mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-05-07 — choose a marketed DIN from the same-category list.Discontinued 2001-05-07 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-05-07 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2001-05-07 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Serax · DIN 02043653 Manufacturer: Wyeth Pharmaceuticals; listing date 1996-10-01 Health Canada: Cancelled post market since 2001-05-07 · brand SERAX TABLETS 10MG · ATC N05BA04 OXAZEPAM · form Tablet · route Oral · ingredients OXAZEPAM 10 MG/TAB · company Wyeth-ayerst canada inc. · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Serax: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17099 · Verify on the e-Formulary ↗ (DIN 02043653)

Source record

DIN 02043653: Serax Raw flags: notABenefit=Y, sec3=Y Item: 281608052; group id 499; item number 1291; lccId None; manufacturer id WAY Source form: Tab; strength: 10mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02043653 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17099

Interchangeable products

Apo-Oxazepam · DIN 00402680 · $0.0350

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02043653

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2001-05-07 — choose a marketed DIN from the same-category list.

Serax · DIN 02043661 · 15mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-05-17 — choose a marketed DIN from the same-category list.Discontinued 2002-05-17 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-05-17 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2002-05-17 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Serax · DIN 02043661 Manufacturer: Wyeth Pharmaceuticals; listing date 1996-10-01 Health Canada: Cancelled post market since 2002-05-17 · brand SERAX TABLETS 15MG · ATC N05BA04 OXAZEPAM · form Tablet · route Oral · ingredients OXAZEPAM 15 MG · company Wyeth-ayerst canada inc. · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Serax: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16575 · Verify on the e-Formulary ↗ (DIN 02043661)

Source record

DIN 02043661: Serax Raw flags: notABenefit=Y, sec3=Y Item: 281608051; group id 499; item number 1292; lccId None; manufacturer id WAY Source form: Tab; strength: 15mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02043661 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16575

Interchangeable products

Apo-Oxazepam · DIN 00402745 · $0.0550

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2002-05-17 — choose a marketed DIN from the same-category list.

Serax · DIN 02043688 · 30mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-10-29 — choose a marketed DIN from the same-category list.Discontinued 2001-10-29 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-10-29 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2001-10-29 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Serax · DIN 02043688 Manufacturer: Wyeth Pharmaceuticals; listing date 1996-10-01 Health Canada: Cancelled post market since 2001-10-29 · brand SERAX TABLETS 30MG · ATC N05BA04 OXAZEPAM · form Tablet · route Oral · ingredients OXAZEPAM 30 MG/TAB · company Wyeth-ayerst canada inc. · schedule Targeted substances (cdsa iv)

Check this DIN again · Health Canada product record

Serax: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16883 · Verify on the e-Formulary ↗ (DIN 02043688)

Source record

DIN 02043688: Serax Raw flags: notABenefit=Y, sec3=Y Item: 281608050; group id 499; item number 1293; lccId None; manufacturer id WAY Source form: Tab; strength: 30mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02043688 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16883

Interchangeable products

Apo-Oxazepam · DIN 00402737 · $0.0750

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2001-10-29 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

ALPRAZOLAM

· 12 products · General benefit (6), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 0.25mg, 0.5mg, 1mg, 2mg · Tab

BROMAZEPAM

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 1.5mg, 3mg, 6mg · Tab

CHLORDIAZEPOXIDE

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 25mg · Cap

CLORAZEPATE DIPOTASSIUM

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 3.75mg, 7.5mg, 15mg · Cap

DIAZEPAM

· 10 products · Limited Use, codes 481 (1), General benefit (6), Listed, not a benefit (3) · strengths: 5mg/mL, 10mg/2mL, 15mg/3mL, 2mg, 5mg, 10mg · Inj Sol (Preservative Free), Rect Gel-2x 5mg Pk, Rect Gel-2x10mg Pk, Rect Gel-2x15mg Pk, Tab

LORAZEPAM

· 12 products · General benefit (9), Listed, not a benefit (3) · strengths: 0.5mg, 1mg, 2mg · Tab

HYDROXYZINE HCL

· 8 products · Listed, not a benefit · strengths: 10mg, 25mg, 50mg · Cap

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more

Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.

Other drugs whose Health Canada label lists a similar indication: anxiety neurosis

From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. LORAZEPAM · General benefit (9), Listed, not a benefit (4), Limited Use, codes 481 (2), Off-Formulary Interchangeable, not an ODB benefit (6) 1 INDICATIONS TEVA-LORAZEPAM (lorazepam) is indicated for: • the short-term relief of manifestations of excessive anxiety in patients with anxiety neurosis. PM: https://pdf.hres.ca/dpd_pm/00070208.PDF; date March 05, 1985; DIN 00637742; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26

What the Health Canada label says it is for

1 INDICATIONS APO-OXAZEPAM (oxazepam tablets) is indicated for the short-term symptomatic relief of excessive anxiety and tension in patients with anxiety neurosis. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. APO-OXAZEPAM also is indicated for relieving the symptoms of acute alcoholic withdrawal, including acute agitation and impending delirium tremens. 1.1 Pediatrics Pediatrics (<18 years of age): APO-OXAZEPAM is contraindicated in infants (see 2 CONTRAINDICATIONS). No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (>65 years of age): Evidence from clinical studies and experiences suggests that use in the geriatric population is associated with differences in safety or effectiveness. Long-term use of APO-OXAZEPAM should be avoided in elderly patients. Enhanced monitoring is recommended (see 4.1 Dosing considerations; 7 WARNING AND PRECAUTIONS, Falls and Fractures). https://pdf.hres.ca/dpd_pm/00072522.PDF PM date: SEP 05, 2023 Source product: APO-OXAZEPAM; DIN 00402680; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Oxazepam · DIN 00402745 Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00402745

Check this DIN again

Other review policies

For Serax: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026